|
(1 of 2) Florida Minority Cancer Research & Training Center: Feasibility Studies
|
5P20CA192990-04
|
$165,747
|
REAMS, ROMONIA
|
FLORIDA AGRICULTURAL AND MECHANICAL UNIV
|
|
(1) Intestinal Organoid Models for APC LOH
|
5R21CA208638-02
|
$192,406
|
GIARDINA, CHARLES
|
UNIVERSITY OF CONNECTICUT STORRS
|
|
(1/2) Ponce Health Sciences University-Moffitt Cancer Center Partnership
|
2U54CA163071-06
|
$1,427,230
|
MATTA, JAIME
|
PONCE SCHOOL OF MEDICINE
|
|
(2/2) CDU/UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities
|
5U54CA143930-08
|
$704,474
|
FARIAS-EISNER, ROBIN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
5R01CA208644-02
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
(PQ3) Cellular and Molecular Mechanisms Driving Myeloid Compartment Variation in Human Triple Negative Breast Cancer
|
1R01CA219880-01
|
$697,539
|
PALUCKA, ANNA KAROLINA
|
JACKSON LABORATORY
|
|
(PQ7) A multi-fluorescent intravital microscopy approach to study osteosarcoma
|
1R21CA208618-01A1
|
$191,221
|
INTINI, GIUSEPPE
|
HARVARD MEDICAL SCHOOL
|
|
(PQ7)Multi-scale Analysis of Tumor Microenvironment Heterogeneity
|
1R01CA208735-01A1
|
$729,393
|
FELSHER, DEAN
|
STANFORD UNIVERSITY
|
|
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle
|
5R21CA205437-03
|
$168,236
|
WANING, DAVID
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer
|
5R01CA190092-04
|
$552,684
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
|
(PQA1) The antipsychotic thioridazine protects against medulloblastoma (MB): volu
|
5R01CA185039-04
|
$373,436
|
JAN, LILY
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQA1)The Molecular Mechanisms Underlying Effects of Aspirin on Colorectal Cancer
|
5R01CA184820-04
|
$386,650
|
DUBOIS, RAYMOND
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
(PQB-4) Single cell analysis strategy for monitoring drug responses of tumors
|
5R01CA190122-04
|
$571,080
|
TIAN, QIANG
|
INSTITUTE FOR SYSTEMS BIOLOGY
|
|
(PQC-5) Zwitterionic NIR/Zr-89 Agents for Prostate Cancer Staging and Treatment
|
5R01CA185457-04
|
$640,378
|
FRANGIONI, JOHN
|
CURADEL, LLC
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132379-08
|
$1,258,708
|
MARTINEZ, MARIA
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192973-04
|
$191,836
|
MANNE, UPENDER
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
15-PGDH in Cholangiocarcinogenesis
|
5R01CA102325-11
|
$344,269
|
WU, TONG
|
TULANE UNIVERSITY OF LOUISIANA
|
|
2/2 NCCU-LCCC Partnership in Cancer Research
|
5U54CA156733-08
|
$919,471
|
EARP, HENRY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
|
2U54CA163068-06
|
$1,656,304
|
MUNOZ-ANTONIA, TERESITA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-04
|
$144,556
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership
|
5U54CA118623-12
|
$407,680
|
TROY, ROBERTA
|
TUSKEGEE UNIVERSITY
|
|
2017 international EMT society meeting
|
1R13CA221310-01
|
$2,000
|
YANG, JING
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
3D Dynamic Contrast-Enhanced US for Monitoring Chemotherapy of Liver Metastasis
|
5R01CA195443-02
|
$252,908
|
WILLMANN, JUERGEN
|
STANFORD UNIVERSITY
|
|
A blood test to identify prostate cancer patients at risk for visceral metastasis
|
1R01CA218356-01
|
$620,500
|
POSADAS, EDWIN
|
CEDARS-SINAI MEDICAL CENTER
|
|
A highly specific NIRF/PET probe for the detection of cancer and metastases
|
1R43CA210854-01A1
|
$224,958
|
Yang, Xinlin
|
IMOL RADIOPHARMACEUTICALS, LLC
|
|
A Microfluidics Approach to Investigate Tumor Cell Trafficking in Bone Marrow
|
1F32CA210540-01A1
|
$58,326
|
GLASER, DREW
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
A Nanopatterned Interdigitated Electrode Array Device for Anti-migratory Cancer Drug Screening
|
1R43CA221659-01
|
$225,000
|
Geisse, Nicholas
|
NANOSURFACE BIOMEDICAL, INC.
|
|
A network platform to connect drug response and prognosis phenotypes for cancers
|
5R01CA196631-02
|
$395,911
|
LI, HU
|
MAYO CLINIC ROCHESTER
|
|
A new imaging approach to radiotherapy planning for lung cancer
|
5R01CA193050-03
|
$535,497
|
RIZI, RAHIM
|
UNIVERSITY OF PENNSYLVANIA
|
|
A NOVEL EXTRACELLULAR AND INTRACELLULAR TREATMENT PARADIGM FOR ERADICATING CANCER
|
5F30CA189435-04
|
$49,044
|
SOM, AVIK
|
WASHINGTON UNIVERSITY
|
|
A Novel Targeted Nanomedicine Delivering MicroRNA-30-5p Replacement Therapy for Multi-drug Resistant Cancer Treatment
|
1U43CA221567-01
|
$299,267
|
Place, Robert
|
MIRECULE, INC.
|
|
A Pathway of Tumor Suppression
|
2R01CA047296-29
|
$366,000
|
LOZANO, GUILLERMINA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
|
1R44CA217591-01
|
$621,000
|
KAHN, STUART
|
SYNTRIX BIOSYSTEMS, INC.
|
|
A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome
|
1R44CA213519-01
|
$999,914
|
ISAACMAN, STEVEN
|
NANOMETICS, LLC
|
|
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy
|
5R44CA206606-02
|
$1,004,186
|
WINRAM, SCOTT
|
CYNVEC, LLC
|
|
A population-based approach to single CTC analysis in metastatic breast cancer outcome
|
1R01CA207468-01A1
|
$498,850
|
YANG, HUSHAN
|
THOMAS JEFFERSON UNIVERSITY
|
|
A simple assay system for rapid detection of circulating tumor cells
|
3R41CA183428-01A1S2
|
$50,000
|
HONG, BIN
|
TELOVISION, LLC
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S1
|
$125,000
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S2
|
$62,491
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-41
|
$7,810,244
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Academy of Behavioral Medicine Research Annual Conference
|
1R13CA216984-01
|
$7,580
|
MCCUBBIN, JAMES
|
CLEMSON UNIVERSITY
|
|
Adaptive resistance to HIF1a inhibition in hypoxia
|
5R01CA207377-02
|
$352,147
|
QIAN, ZHENG DAVID
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
Aerosolized platinum nanoparticle chemotherapy for lung cancer
|
1R43CA203142-01A1
|
$298,065
|
GROER, CHAD
|
NANOPHARM, LLC
|
|
Alternatively Spliced Tissue Factor and Pathobiology of Pancreatic Cancer
|
5R01CA190717-03
|
$276,298
|
BOGDANOV, VLADIMIR
|
UNIVERSITY OF CINCINNATI
|
|
AMPK Regulation of Microtubule Dynamics in Breast Cancer Metastasis
|
3F30CA196075-02S1
|
$6,646
|
CHAKRABARTI, KRISTI
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
An organotypic model recapitulating colon cancer microenvironment and metastasis
|
1U01CA214300-01A1
|
$560,162
|
HUANG, EMINA
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer
|
5R01CA208254-02
|
$481,793
|
SWEENEY, CHRISTOPHER
|
DANA-FARBER CANCER INST
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,094,457
|
Barr, Frederic
|
CCR (NCI)
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|